{"api":"v1","generated_at":"2026-10-01T10:18:59.906Z","licence":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/","attribution":"TOLL, with a link to the page cited"},"page":"https://tollindex.com/e/api-magentlab-com-api-calc-prevail-a674f8","pinned_page":"https://tollindex.com/e/api-magentlab-com-api-calc-prevail-a674f8/at/2026-10-01T05-50Z","pinned":false,"method":"https://tollindex.com/ledger/method","snapshot_at":"2026-10-01T05:50:06.230Z","snapshot_stamp":"2026-10-01T05-50Z","endpoint":{"slug":"api-magentlab-com-api-calc-prevail-a674f8","canonical_url":"https://api.magentlab.com/api/calc/prevail","resource":"https://api.magentlab.com/api/calc/prevail","http_method":"POST","type":"http","x402_version":2,"registries":["cdp"],"primary_registry":"cdp","curated_by_coinbase":false,"description":"Armstrong 2018 PREVAIL Cox linear predictor for overall survival in chemotherapy-naïve metastatic castration-resistant prostate cancer from albumin, ALP versus ULN, bone metastases under 10, hemoglobin, LDH versus ULN, NLR under 2.5, pain 0-1, liver metastases, ln(PSA), months from diagnosis, and enzalutamide versus placebo. Table 1 HRs as ln(HR). Not a 1-/2-/3-year OS percent (no published S0). magent does not read bone scans. Not a dose or treatment order.","service_name":"magent","declared_category":null,"declared_tags":["prevail","mcrpc","prostate-cancer","survival","calculator"],"route_template":null,"registry_updated":"2026-09-28T13:55:07.755Z"},"derived":{"note":"fields no registry supplies; TOLL derives them and marks them derived on the page","title":"calc prevail","category":"other","first_observed_by_toll":"2026-09-28T13:51:25.436Z","last_observed_by_toll":"2026-10-01T05:50:06.230Z","observation_began":"2026-09-10"},"presence":{"listed_now":true,"first_absent_at":null,"delisting_confirmed_at":null,"events":[{"registry":"cdp","at":"2026-09-28T13:51:25.437Z","event":"listed"}]},"accepts":[{"registry":"cdp","ordinal":0,"network":"eip155:8453","asset":"0x833589fcd6edb6e08f4c7c32d4f71b54bda02913","asset_name":"USD Coin","symbol":"USDC","decimals":6,"amount_display":"0.005 USDC","amount_units":0.005,"decimals_known":true,"pay_to":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","scheme":"exact"}],"counters":{"observed_at":"2026-10-01T05:50:06.230Z","calls_30d":2,"unique_payers_30d":1,"last_called_at":"2026-09-28T13:55:07.620Z"},"validation":{"latest":{"observed_at":"2026-10-01T08:50:19.649Z","state":"pass","failed_checks":[],"endpoint_http_status":402,"run_id":"daily-2026-10-01"},"uptime":[{"days":7,"observed":5,"passed":5,"ratio":1},{"days":30,"observed":5,"passed":5,"ratio":1},{"days":90,"observed":5,"passed":5,"ratio":1}],"history_90d":[{"observed_at":"2026-10-01T08:50:19.649Z","state":"pass","failed_checks":[],"run_id":"daily-2026-10-01","state_changed":false},{"observed_at":"2026-09-30T08:14:38.902Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-30","state_changed":false},{"observed_at":"2026-09-29T20:24:20.601Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-29","state_changed":false},{"observed_at":"2026-09-28T17:32:05.302Z","state":"pass","failed_checks":[],"run_id":"daily-2026-09-28","state_changed":false},{"observed_at":"2026-09-28T16:46:32.018Z","state":"pass","failed_checks":[],"run_id":"new-after-daily-2026-09-28","state_changed":true}]},"seller":{"wallet":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","page":"https://tollindex.com/seller/0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","endpoints":844,"hosts":1},"reports":0,"registry_record":{"cdp":[{"tags":["prevail","mcrpc","prostate-cancer","survival","calculator"],"type":"http","accepts":[{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"USD Coin","version":"2","paymentFlow":"upfront","resourceUrl":"https://api.magentlab.com/api/calc/prevail","assetTransferMethod":"eip3009"},"payTo":"0x836Be278f1739fB4308091cD1852F7971Bc19Ee2","amount":"5000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":600}],"quality":{"lastCalledAt":"2026-09-28T13:55:07.62Z","l30DaysTotalCalls":2,"l30DaysUniquePayers":1},"resource":"https://api.magentlab.com/api/calc/prevail","extensions":{"bazaar":{"info":{"input":{"body":{"items":[{"psa_ng_ml":20,"nlr_lt_2_5":true,"pain_0_to_1":true,"albumin_g_dl":4,"alp_below_uln":true,"ldh_below_uln":true,"bone_mets_lt_10":true,"hemoglobin_g_dl":13,"no_liver_metastases":true,"months_since_diagnosis":60,"treatment_enzalutamide":true},{"psa_ng_ml":20,"nlr_lt_2_5":true,"pain_0_to_1":true,"albumin_g_dl":4,"alp_below_uln":true,"ldh_below_uln":true,"bone_mets_lt_10":true,"hemoglobin_g_dl":13,"no_liver_metastases":true,"months_since_diagnosis":60,"treatment_enzalutamide":true}]},"type":"http","method":"POST"},"output":{"type":"json","example":{"path":"/api/calc/prevail","count":2,"items":[{"formula":"prevail","citation":{"id":"armstrong-2018-prevail","doi":"10.1093/annonc/mdy406","pmid":"30202945","title":"Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer","source":"Ann Oncol. 2018;29(11):2200-2209","authors":"Armstrong AJ, Lin P, Higano CS, et al."},"psa_ng_ml":20,"disclaimer":"Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.","nlr_lt_2_5":true,"risk_score":-5.796122,"pain_0_to_1":true,"albumin_g_dl":4,"alp_below_uln":true,"ldh_below_uln":true,"bone_mets_lt_10":true,"hemoglobin_g_dl":13,"linear_predictor":-5.796122,"formula_expression":"lp = ln(0.71)*albumin_g_dl + ln(0.79)*alp_below_uln + ln(0.68)*bone_mets_lt_10 + ln(0.85)*hemoglobin_g_dl + ln(0.67)*ldh_below_uln + ln(0.69)*nlr_lt_2_5 + ln(0.77)*pain_0_to_1 + ln(0.49)*no_liver_metastases + ln(1.23)*ln(psa_ng_ml) + ln(0.997)*months_since_diagnosis + ln(0.68)*treatment_enzalutamide; Armstrong 2018 Table 1 multivariable HRs, β = ln(HR); A versus B codes A as 1; booleans contribute β when true else 0; no printed S0; not 1-/2-/3-year OS percents; not nomogram points; training-set tertiles unpublished as numeric cutoffs; chemotherapy-naïve mCRPC PREVAIL; magent does not read bone scans","no_liver_metastases":true,"months_since_diagnosis":60,"treatment_enzalutamide":true},{"formula":"prevail","citation":{"id":"armstrong-2018-prevail","doi":"10.1093/annonc/mdy406","pmid":"30202945","title":"Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer","source":"Ann Oncol. 2018;29(11):2200-2209","authors":"Armstrong AJ, Lin P, Higano CS, et al."},"psa_ng_ml":20,"disclaimer":"Not a medical device. Deterministic published-formula or published-code output for autonomous agents. A licensed clinician remains responsible for patient care and billing submissions.","nlr_lt_2_5":true,"risk_score":-5.796122,"pain_0_to_1":true,"albumin_g_dl":4,"alp_below_uln":true,"ldh_below_uln":true,"bone_mets_lt_10":true,"hemoglobin_g_dl":13,"linear_predictor":-5.796122,"formula_expression":"lp = ln(0.71)*albumin_g_dl + ln(0.79)*alp_below_uln + ln(0.68)*bone_mets_lt_10 + ln(0.85)*hemoglobin_g_dl + ln(0.67)*ldh_below_uln + ln(0.69)*nlr_lt_2_5 + ln(0.77)*pain_0_to_1 + ln(0.49)*no_liver_metastases + ln(1.23)*ln(psa_ng_ml) + ln(0.997)*months_since_diagnosis + ln(0.68)*treatment_enzalutamide; Armstrong 2018 Table 1 multivariable HRs, β = ln(HR); A versus B codes A as 1; booleans contribute β when true else 0; no printed S0; not 1-/2-/3-year OS percents; not nomogram points; training-set tertiles unpublished as numeric cutoffs; chemotherapy-naïve mCRPC PREVAIL; magent does not read bone scans","no_liver_metastases":true,"months_since_diagnosis":60,"treatment_enzalutamide":true}]}},"iconUrl":"https://api.magentlab.com/favicon.ico"},"schema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"body":{"type":"object","required":["items"],"properties":{"items":{"type":"array","items":{"type":"object","required":["albumin_g_dl","alp_below_uln","bone_mets_lt_10","hemoglobin_g_dl","ldh_below_uln","nlr_lt_2_5","pain_0_to_1","no_liver_metastases","psa_ng_ml","months_since_diagnosis","treatment_enzalutamide"],"properties":{"psa_ng_ml":{"type":"number","description":"Baseline PSA in ng/mL (0.1-10000). Table 1: continuous log_e PSA, HR 1.23 per ln(ng/mL). magent does not assay PSA."},"nlr_lt_2_5":{"type":"boolean","description":"Neutrophil-to-lymphocyte ratio <2.5 as assigned by the caller (true or false). Table 1: true (<2.5 versus ≥2.5) has HR 0.69. magent does not compute NLR from counts."},"pain_0_to_1":{"type":"boolean","description":"Pain score 0-1 versus ≥2 on the paper's linear scale, as assigned by the caller (true or false). Table 1: true (0-1 versus ≥2) has HR 0.77. magent does not assign pain scores."},"albumin_g_dl":{"type":"number","description":"Serum albumin in g/dL (1.0-6.5). Armstrong 2018 Table 1: continuous, HR 0.71 per g/dL. magent does not assay albumin."},"alp_below_uln":{"type":"boolean","description":"Alkaline phosphatase below the institutional ULN as assigned by the caller (true or false). Table 1: true (<ULN versus ≥ULN) has HR 0.79. magent does not assay ALP or apply ULN."},"ldh_below_uln":{"type":"boolean","description":"Lactate dehydrogenase below the institutional ULN as assigned by the caller (true or false). Table 1: true (<ULN versus ≥1×ULN) has HR 0.67. magent does not assay LDH or apply ULN."},"bone_mets_lt_10":{"type":"boolean","description":"Fewer than 10 bone metastases as assigned by the caller (true or false). Table 1: true (<10 versus ≥10) has HR 0.68. magent does not read bone scans."},"hemoglobin_g_dl":{"type":"number","description":"Hemoglobin in g/dL (3.0-22.0). Table 1: continuous, HR 0.85 per g/dL. magent does not assay hemoglobin."},"no_liver_metastases":{"type":"boolean","description":"No liver metastases as assigned by the caller (true or false). Table 1 pattern of spread: true (no liver metastases versus any liver metastases) has HR 0.49. magent does not read imaging."},"months_since_diagnosis":{"type":"number","description":"Time from diagnosis to randomization in months (0-720). Table 1: continuous, HR 0.997 per month. magent does not date the interval."},"treatment_enzalutamide":{"type":"boolean","description":"true if the PREVAIL treatment term is enzalutamide, false if placebo. Table 1: true (enzalutamide versus placebo) has HR 0.68. Not a dose or treatment order."}}},"maxItems":25,"minItems":1}},"additionalProperties":false},"type":{"type":"string","const":"http"},"method":{"type":"string","const":"POST"},"headers":{"type":"object","additionalProperties":{"type":"string"}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"example":{"type":"object"}}}}}}},"description":"Armstrong 2018 PREVAIL Cox linear predictor for overall survival in chemotherapy-naïve metastatic castration-resistant prostate cancer from albumin, ALP versus ULN, bone metastases under 10, hemoglobin, LDH versus ULN, NLR under 2.5, pain 0-1, liver metastases, ln(PSA), months from diagnosis, and enzalutamide versus placebo. Table 1 HRs as ln(HR). Not a 1-/2-/3-year OS percent (no published S0). magent does not read bone scans. Not a dose or treatment order.","lastUpdated":"2026-09-28T13:55:07.755Z","serviceName":"magent","x402Version":2}]}}